KNSA
Kiniksa Pharmaceuticals, Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
61.40
PEG
0.26
P/B
6.48
P/S
5.43
EV/EBITDA
41.22
DCF Value
$-770.96
FCF Yield
3.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.6%
Operating Margin
11.4%
Net Margin
8.7%
ROE
11.5%
ROA
7.7%
ROIC
8.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $202.1M | $14.2M | $0.18 |
| FY 2025 | $677.6M | $59.0M | $0.75 |
| Q3 2025 | $180.9M | $18.4M | $0.23 |
| Q2 2025 | $156.8M | $17.8M | $0.23 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
BM
Exchange
NASDAQ
Beta
0.06
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.